Skip to content

Publications

Publications

INSERM U1218 members 2018-2020 publications

Only publications whose first or last author is a INSERM U1218 staff were selected

1: Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. PMID: 29650362.

2: Carvalho SD, Pissaloux D, Crombé A, Coindre JM, Le Loarer F. Pleomorphic Sarcomas: The State of the Art. Surg Pathol Clin. 2019 Mar;12(1):63-105. doi: 10.1016/j.path.2018.10.004. Epub 2018 Dec 17. PMID: 30709449.

3: Widemann BC, Italiano A. Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. J Clin Oncol. 2018 Jan 10;36(2):160-167. doi: 10.1200/JCO.2017.75.3467. Epub 2017 Dec 8. PMID: 29220302; PMCID: PMC5759316.

4: Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, Yvorel V,  Pissaloux D, Thomas de Montpreville V, Masliah-Planchon J, Lantuejoul S, Brevet M, Blay JY, Coindre JM, Tirode F, Le Loarer F. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses. Am J Surg Pathol. 2019 Apr;43(4):455-465. doi: 10.1097/PAS.0000000000001188. PMID: 30451731.

5: Lucchesi C, Khalifa E, Laizet Y, Soubeyran I, Mathoulin-Pelissier S, Chomienne C, Italiano A. Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy. JAMA Oncol. 2018 Oct 1;4(10):1398-1404. doi: 10.1001/jamaoncol.2018.0723. PMID: 29801054; PMCID: PMC6233783.

6: Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, Ryckewaert T, Bessede A, Ghiringhelli F, Pulido M, Italiano A. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jan  1;4(1):93-97. doi: 10.1001/jamaoncol.2017.1617. PMID: 28662235; PMCID: PMC5833654.

7: Leiner J, Le Loarer F. The current landscape of rhabdomyosarcomas: an update. Virchows Arch. 2020 Jan;476(1):97-108. doi: 10.1007/s00428-019-02676-9. Epub 2019 Nov 6. PMID: 31696361.

8: Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May PMID: 29735299.

9: Chakiba C, Bellera C, Etchepare F, Mathoulin-Pelissier S, Rainfray M,  Soubeyran P. The prognostic value of G8 for functional decline. J Geriatr Oncol.  2019 Nov;10(6):921-925. doi: 10.1016/j.jgo.2018.12.004. Epub 2019 Jan 9. PMID:  30638869.

10: Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10. PMID: 31292142.

11: Fouquet C, Le Rouzic MA, Leblanc T, Fouyssac F, Leverger G, Hessissen L, Marlin S, Bourrat E, Fahd M, Raffoux E, Vannier JP, Jäkel N, Knoefler R, Triolo V, Pasquet M, Bayart S, Thuret I, Lutz P, Vermylen C, Touati M, Rose C, Matthes T, Isidor B, Kannengiesser C, Ducassou S. Genotype/phenotype correlations of childhood-onset congenital sideroblastic anaemia in a European cohort. Br J Haematol. 2019 Nov;187(4):530-542. doi: 10.1111/bjh.16100. Epub 2019 Jul 23. PMID: 31338833.

12: Le Loarer F, Pissaloux D, Watson S, Godfraind C, Galmiche-Rolland L, Silva K, Mayeur L, Italiano A, Michot A, Pierron G, Vasiljevic A, Ranchère-Vince D, Coindre JM, Tirode F. Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. Am J Surg Pathol. 2019  Feb;43(2):268-276. doi: 10.1097/PAS.0000000000001187. PMID: 30407212.

13: Cousin S, Khalifa E, Crombe A, Laizet Y, Lucchesi C, Toulmonde M, Le Moulec S, Auzanneau C, Soubeyran I, Italiano A. Targeting ERBB2 mutations in solid tumors: biological and clinical implications. J Hematol Oncol. 2018 Jun 25;11(1):86. doi: 10.1186/s13045-018-0630-4. PMID: 29941010; PMCID: PMC6019715.

14: Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20. PMID: 29459949.

15: Etienne G, Dulucq S, Huguet F, Schmitt A, Lascaux A, Hayette S, Fort MP,  Sujobert P, Bijou F, Morisset S, Tavitian S, Bidet A, Turcq B, Robbesyn F, Chollet C, Belloc F, Durrieu F, Mahon FX, Nicolini FE. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Med. 2019 Sep;8(11):5173-5182. doi: 10.1002/cam4.2410. Epub 2019 Jul 27. PMID: 31350815; PMCID: PMC6718576.

16: Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann Oncol. 2018 May 1;29(5):1304-1311. doi: 10.1093/annonc/mdy076. PMID: 29788155.

17: Delom F, Nazaraliyev A, Fessart D. The role of protein disulphide isomerase AGR2 in the tumour niche. Biol Cell. 2018 Dec;110(12):271-282. doi: 10.1111/boc.201800024. Epub 2018 Oct 14. PMID: 30238476.

18: Laurent E, Begueret H, Bonhomme B, Veillon R, Thumerel M, Velasco V, Brouste V, Hoppe S, Fournier M, Grellety T, MacGrogan G. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. Am J Surg Pathol. 2019 Mar;43(3):293-302. doi: 10.1097/PAS.0000000000001216. PMID: 30628926.

19: Huguet F, Cayuela JM, Cambier N, Carpentier N, Tindel M, Violet I, Zunic P, Lascaux A, Etienne G; AdheRMC Investigators. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. Br J Haematol. 2019 Dec;187(5):615-626. doi: 10.1111/bjh.16145. Epub 2019 Aug 8. PMID: 31394591.

20: Le Cesne A, Marec-Berard P, Blay JY, Gaspar N, Bertucci F, Penel N, Bompas E, Cousin S, Toulmonde M, Bessede A, Fridman WH, Sautes-Fridman C, Kind M, Le Loarer F, Pulido M, Italiano A. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer. 2019 Sep;119:151-157. doi: 10.1016/j.ejca.2019.07.018. Epub 2019 Aug 21. PMID: 31442817.

21: Grellety T, Callens C, Richard E, Briaux A, Vélasco V, Pulido M, Gonçalves A, Gestraud P, MacGrogan G, Bonnefoi H, Cardinaud B. Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target. Clin Cancer Res. 2019 Jan 15;25(2):856-867. doi: 10.1158/1078-0432.CCR-18-1469. Epub 2018 Oct 23. PMID: 30352905.

22: Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A. Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. Clin Cancer Res. 2019 Aug 1;25(15):4611-4615. doi: 10.1158/1078-0432.CCR-18-3127. Epub 2019 Apr 12. Erratum in: Clin Cancer Res. 2019 Aug 1;25(15):4859. PMID: 30979737.

23: Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D; EORTC 10994/BIG 1-00 study investigators. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. Br J Cancer. 2019 Apr;120(9):913-921. doi: 10.1038/s41416-019-0420-y. Epub 2019 Mar 22. PMID: 30899086; PMCID: PMC6734658.

24: Le Quang M, Ranchère-Vince D, Le Loarer F. Aspects morphologiques et moléculaires des tumeurs malignes associées à une dérégulation des complexes BAF [Pathological and molecular features of malignancies underlined by BAF complexes inactivation]. Ann Pathol. 2019 Dec;39(6):399-413. French. doi: 10.1016/j.annpat.2019.05.001. Epub 2019 Jun 27. PMID: 31255411.

25: Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques). Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019 Nov;187(3):337-346. doi: 10.1111/bjh.16083. Epub 2019 Jul 4. PMID: 31271217.

26: Le Loarer F, Laffont S, Lesluyes T, Tirode F, Antonescu C, Baglin AC, Delespaul L, Soubeyran I, Hostein I, Pérot G, Chibon F, Baud J, Le Guellec S, Karanian M, Costes-Martineau V, Castain C, Eimer S, Le Bail B, Wassef M, CoindreClinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum. Am J Surg Pathol. 2019 Jun;43(6):747-754. doi: 10.1097/PAS.0000000000001238. PMID: 30829729.

27: Soubeyran PL, Cordoba R. Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas. Curr Opin Oncol. 2019 Sep;31(5):369-373. doi: 10.1097/CCO.0000000000000559. PMID: 31335827.

28: Delcroix V, Mauduit O, Tessier N, Montillaud A, Lesluyes T, Ducret T, Chibon F, Van Coppenolle F, Ducreux S, Vacher P. The Role of the Anti-Aging Protein Klotho in IGF-1 Signaling and Reticular Calcium Leak: Impact on the Chemosensitivity of Dedifferentiated Liposarcomas. Cancers (Basel). 2018 Nov 14;10(11):439. doi: 10.3390/cancers10110439. PMID: 30441794; PMCID: PMC6266342.

29: Dumas PY, Bérard E, Bréal C, Dulucq S, Réa D, Nicolini F, Forcade E, Dufossée M, Pasquet JM, Turcq B, Bidet A, Milpied N, Déchanet-Merville J, Lafarge X, Etienne G, Mahon FX; French Intergroup in Chronic Myeloid Leukemia. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission. Cancer Med. 2019 Sep;8(11):4976-4985. doi: 10.1002/cam4.2371. Epub 2019 Jul 9. PMID: 31287239; PMCID: PMC6718597.

30: Sawai CM, Serpas L, Neto AG, Jang G, Rashidfarrokhi A, Kolbeck R, Sanjuan MA, Reizis B, Sisirak V. Plasmacytoid Dendritic Cells Are Largely Dispensable for the Pathogenesis of Experimental Inflammatory Bowel Disease. Front Immunol. 2018 Oct 25;9:2475. doi: 10.3389/fimmu.2018.02475. PMID: 30410494; PMCID: PMC6209677.

31: Fourneaux B, Bourdon A, Dadone B, Lucchesi C, Daigle SR, Richard E, Laroche-Clary A, Le Loarer F, Italiano A. Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition. J Hematol Oncol. 2019 Jan 25;12(1):11. doi: 10.1186/s13045-018-0694-1. PMID: 30683135; PMCID: PMC6347793.

32: Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. doi:  10.1016/S1470-2045(19)30276-1. Epub 2019 Jul 19. PMID: 31331699.

33: Lichou F, Orazio S, Dulucq S, Etienne G, Longy M, Hubert C, Groppi A, Monnereau A, Mahon FX, Turcq B. Novel analytical methods to interpret large sequencing data from small sample sizes. Hum Genomics. 2019 Aug 30;13(1):41. doi: 10.1186/s40246-019-0235-1. PMID: 31470908; PMCID: PMC6717342.

34: Cousin S, Seneschal J, Italiano A. Toxicity profiles of immunotherapy. Pharmacol Ther. 2018 Jan;181:91-100. doi: 10.1016/j.pharmthera.2017.07.005. Epub 2017 Jul 15. PMID: 28716652.

35: Delom F, Mohtar MA, Hupp T, Fessart D. The anterior gradient-2 interactome. Am J Physiol Cell Physiol. 2020 Jan 1;318(1):C40-C47. doi: 10.1152/ajpcell.00532.2018. Epub 2019 Oct 23. PMID: 31644305.

36: Nicolini FE, Alcazer V, Cony-Makhoul P, Heiblig M, Morisset S, Fossard G, Bidet A, Schmitt A, Sobh M, Hayette S, Mahon FX, Dulucq S, Etienne G. Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. Exp Hematol. 2018 Aug;64:97-105.e4. doi: 10.1016/j.exphem.2018.05.003. Epub 2018 May 23. PMID: 29800673.

37: Italiano A. Olaratumab failure in sarcomas: what are the lessons learned? Eur J Cancer. 2019 Aug;117:69-70. doi: 10.1016/j.ejca.2019.04.030. Epub 2019 JunPMID: 31254941.

38: Aalders KC, Touati N, Tryfonidis K, Annonay M, Litiere S, Bergh J, Bodmer A, Cameron DA, Bonnefoi HR; EORTC 10994/BIG 1-00 Study Investigators. Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC  0994/BIG-1-00 trial. Breast Cancer Res Treat. 2018 Jun;169(3):497-505. doi: 10.1007/s10549-018-4698-x. Epub 2018 Feb 12. PMID: 29435853.

39: Italiano A. Pazopanib for progressive desmoid tumours: children, persistant effects, and cost – Author’s reply. Lancet Oncol. 2019 Oct;20(10):e556. doi: 10.1016/S1470-2045(19)30575-3. Epub 2019 Sep 30. PMID: 31578998.

40: Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A. Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. Clin Cancer Res. 2019 Aug 1;25(15):4859. doi: 10.1158/1078-0432.CCR-19-1599. Erratum for: Clin Cancer Res. 2019 Aug 1;25(15):4611-4615. PMID: 31371309.

41: Brunet M, Khalifa E, Italiano A. Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma. Front Oncol. 2019 Nov 12;9:1204. doi: 10.3389/fonc.2019.01204. PMID: 31781502; PMCID: PMC6861385.

42: Laroche-Clary A, Lucchesi C, Rey C, Verbeke S, Bourdon A, Chaire V, Algéo MP, Cousin S, Toulmonde M, Vélasco V, Shutzman J, Savina A, Le Loarer F, Italiano A. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29(4):1023-1029. doi: 10.1093/annonc/mdy039. PMID: 29409053.

43: Upadhaya S, Reizis B, Sawai CM. New genetic tools for the in vivo study of hematopoietic stem cell function. Exp Hematol. 2018 May;61:26-35. doi: 10.1016/j.exphem.2018.02.004. Epub 2018 Mar 6. PMID: 29501466; PMCID: PMC5899657.

44: Bourcier K, Italiano A. Newer therapeutic strategies for soft-tissue  sarcomas. Pharmacol Ther. 2018 Aug;188:118-123. doi: 10.1016/j.pharmthera.2018.02.014. Epub 2018 Feb 24. PMID: 29481809.

45: Auguste P, Leitinger B, Liard C, Rocher V, Azema L, Saltel F, Santamaria D. Meeting report – first discoidin domain receptors meeting. J Cell Sci. 2020 Feb 24;133(4):jcs243824. doi: 10.1242/jcs.243824. PMID: 32094286.

46: Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020 May;189(3):452-468. doi: 10.1111/bjh.16408. Epub 2020 Feb 19. PMID: 32072631.

47: Italiano A. Targeting epigenetics in sarcomas through EZH2 inhibition. J Hematol Oncol. 2020 Apr 7;13(1):33. doi: 10.1186/s13045-020-00868-4. PMID: 32264965; PMCID: PMC7140314.

48: Robert J. Alimentation « biologique » et risque de cancer : une étude de grande qualité et des réactions inappropriées [Organic food consumption and cancer risk: A high-quality study and inappropriate reactions]. Bull Cancer. 2019 Jan;106(1):5-8. French. doi: 10.1016/j.bulcan.2018.11.007. Epub 2018 DecPMID: 30583792.

49: Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S, Richard E, Brouste V, Bonnefoi H, MacGrogan G. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.  Breast Cancer Res Treat. 2020 Jan;179(1):11-23. doi: 10.1007/s10549-019-05437-z. Epub 2019 Sep 16. PMID: 31529299.

50: Ambrogio C, Darbo E, Lee SW, Santamaría D. A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance. Cell Adh Migr. 2018;12(4):394-397. doi: 10.1080/19336918.2018.1445954. Epub 2018 Apr 3. PMID: 29505315; PMCID: PMC6363036.

51: Massé J, Truntzer C, Boidot R, Khalifa E, Pérot G, Velasco V, Mayeur L, Billerey-Larmonier C, Blanchard L, Charitansky H, Soubeyran I, Iggo R, Arnould L, MacGrogan G. Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH  and CREBBP mutations. Mod Pathol. 2020 Jun;33(6):1041-1055. doi: 10.1038/s41379-019-0425-3. Epub 2019 Dec 19. PMID: 31857685.

52: Italiano A. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma? Curr Treat Options Oncol. 2018 Dec 7;19(12):78. doi: 10.1007/s11864-018-0589-y. PMID: 30523434.

53: Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, Salas S, Bonhomme B, Gomez-Brouchet A, Laurent C, Le Guellec S, Audard V, Giraud A, Ramos-Oliver I, Cleton-Jansen AM, Savci-Heijink DC, Kroon HM, Baud J, Pissaloux D, Pierron G, Sherwood A,  oindre JM, Bovée JVMG, Larousserie F, Tirode F. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020 Mar;33(3):404-419. doi: 10.1038/s41379-019-0323-8. Epub 2019 Aug 5. PMID: 31383960.

54: Bonnefoi H, Chakiba C. Category “viewpoints and debates” Is trastuzumab as a single agent obsolete in early breast cancer? Yes. Breast. 2019 Feb;43:146-148. doi: 10.1016/j.breast.2018.10.008. Epub 2018 Oct 20. PMID: 30739644.

55: Robert J. Au-delà du génome : implication de l’épigénome dans l’oncogenèse et la progression des cancers [Beyond the genome: Epigenome involvement in oncogenesis and cancer progression]. Bull Cancer. 2019 Oct;106(10):821-822. French. doi:  10.1016/j.bulcan.2019.09.001. PMID: 31561757.

56: Paillaud E, Cudennec T, Caillet P, Bellera C, Mathoulin-Pélissier S, Soubeyran P. Essais cliniques et personnes âgées cancéreuses, l’outil Geriatric Core Dataset (G-Code) [Clinical trials and elderly patients with cancer, the Geriatric Core Dataset (G-Code) tool]. Soins Gerontol. 2019 May-Jun;24(137):35-37. French. doi: 10.1016/j.sger.2019.03.010. PMID: 31084807.

57: Perret RE, Jullie ML, Vergier B, Coindre JM, Le Loarer F. A subset of so-called dermal non-neural granular cell tumours are underlined by ALK fusions, further supporting the idea that they represent a variant of epithelioid fibrous histiocytoma. Histopathology. 2018  Sep;73(3):532-534. doi: 10.1111/his.13645. Epub 2018 Jun 25. PMID: 29742298.

58: Italiano A, Bringer S, Blay JY, Bonvalot S, Le Cesne A, Le Loarer F, MaingonPatterns of Care and Outcome Radiation-Induced Soft Tissue Sarcomas. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):449-452. doi: 10.1016/j.ijrobp.2018.09.028. Epub 2018 Oct 5. PMID:  0296473.

59: Perrier L, Rascle P, Morelle M, Toulmonde M, Ranchere Vince D, Le Cesne A, Terrier P, Neuville A, Meeus P, Farsi F, Ducimetière F, Blay JY, Ray Coquard I, Coindre JM. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST,  nd desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. PLoS One. 2018 Apr 5;13(4):e0193330. doi: 10.1371/journal.pone.0193330. PMID: 29621244; PMCID: PMC5886412.

60: Rea D, Mahon FX. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy. Br J Haematol. 2018 Jan;180(1):24-32. doi: 10.1111/bjh.14973. Epub 2017 Oct 19. PMID: 29048128.

61: Mahon FX, Hughes TP. Treatment-Free Remission After Second-Line Nilotinib Treatment. Ann Intern Med. 2018 Oct 2;169(7):510. doi: 10.7326/L18-0431. PMID: 30285197.

62: Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, Berton-Rigaud D, Sablin MP, Lesoin A, Rezai K, Lokiec FM, Lhomme C, Bosq J, Bexon AS, Gilles EM, Proniuk S, Dieras V, Jackson DM, Zukiwski A, Italiano A. Phase I study of onapristone, a type I  ntiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS One. 2018 Oct 10;13(10):e0204973. doi: 10.1371/journal.pone.0204973. PMID: 30304013; PMCID: PMC6179222.

63: Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Mar;21(3):446-455. doi: 10.1016/S1470-2045(19)30825-3. Epub 2020 FebPMID: 32078813.

64: Toulmonde M, Italiano A. PD-1 inhibition in sarcoma still needs investigation. Lancet Oncol. 2018 Jan;19(1):e6. doi: 10.1016/S1470-2045(17)30921-X. PMID: 29304365.

65: Ben-Ami E, Perret R, Huang Y, Courgeon F, Gokhale PC, Laroche-Clary A, Eschle BK, Velasco V, Le Loarer F, Algeo MP, Purcell J, Demetri GD, Italiano A. LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. Cancers (Basel). 2020 Mar 23;12(3):757. doi: 10.3390/cancers12030757. PMID: 32210091; PMCID: PMC7140027.

66: Italiano A. Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018 Sep 20;379(12):1189. doi: 10.1056/NEJMc1808907. PMID: 30231221.

67: Italiano A, Stoeckle E. Role of perioperative chemotherapy in soft-tissue sarcomas: It’s time to end a never-ending story. Eur J Cancer. 2018 Jul;97:53-54. doi: 10.1016/j.ejca.2018.03.033. Epub 2018 May 3. PMID: 29731228.

68: Bourcier K, Dinart D, Le Cesne A, Honoré C, Meeus P, Blay JY, Michot A, Le Loarer F, Italiano A. Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis. Oncologist. 2019 Jul;24(7):e559-e564. doi: 10.1634/theoncologist.2018-0641. Epub 2019 Apr 23. PMID: 31015315; PMCID: PMC6656454.

69: Obacz J, Sommerova L, Sicari D, Durech M, Avril T, Iuliano F, Pastorekova S, Hrstka R, Chevet E, Delom F, Fessart D. Extracellular AGR3 regulates breast cancer cells migration via Src signaling. Oncol Lett. 2019 Nov;18(5):4449-4456. doi: 10.3892/ol.2019.10849. Epub 2019 Sep 10. PMID: 31611954; PMCID: PMC6781763

70: Perret R, Escuriol J, Velasco V, Mayeur L, Soubeyran I, Delfour C, Aubert S, Polivka M, Karanian M, Meurgey A, Le Guellec S, Weingertner N, Hoeller S, Coindre JM, Larousserie F, Pierron G, Tirode F, Le Loarer F. NFATc2-rearranged sarcomas: clinicopathologic,  molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker. Mod Pathol. 2020 Apr 23. doi: 10.1038/s41379-020-0542-z. Epub ahead of print. Erratum in: Mod Pathol. 2020 May 15;: PMID: 32327700.

71: Ducassou S, Gourdonneau A, Fernandes H, Leverger G, Pasquet M, Fouyssac F, Bayart S, Bertrand Y, Michel G, Jeziorski E, Thomas C, Abouchallah W, Viard F, Guitton C, Cheikh N, Pellier I, Carausu L, Droz C, Leblanc T, Aladjidi N; Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE). Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol. 2020 Jun;189(5):931-942. doi: 10.1111/bjh.16448. Epub 2020 Mar 4. PMID: 32130726.

72: Dulucq S, Etienne G, Morisset S, Klein E, Chollet C, Robbesyn F, Turcq B, Tigaud I, Hayette S, Nicolini FE, Mahon FX. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line. Ann Hematol. 2019 May;98(5):1159-1168. doi: 10.1007/s00277-019-03633-x. Epub 2019 Feb 23. PMID: 30798348.

73: Nafia I, Toulmonde M, Bortolotto D, Chaibi A, Bodet D, Rey C, Velasco V, Larmonier CB, Cerf L, Adam J, Le Loarer F, Savina A, Bessede A, Italiano A. IDO Targeting in Sarcoma: Biological and Clinical Implications. Front Immunol. 2020 Mar 5;11:274. doi: 10.3389/fimmu.2020.00274. PMID: 32194552; PMCID: PMC7066301.

74: Italiano A, Touati N, Litière S, Collin F, Pourquier P, Gronchi A. Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. Cancer Med. 2018 May;7(5):1575-1577. doi: 10.1002/cam4.1403. Epub 2018 Apr 15. PMID: 29656586; PMCID: PMC5943428.

75: Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3. PMID: 29723417.

76: Klein E, Derrieux C, Dulucq S. Hemophagocytosis by blasts in acute lymphoblastic leukemia. Blood Res. 2019 Mar;54(1):2. doi: 10.5045/br.2019.54.1.2. Epub 2019 Mar 21. PMID: 30956954; PMCID: PMC6439298.

77: Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018 Jun 7;378(23):2242-2243. doi: 10.1056/NEJMc1803837. PMID: 29874526.

78: Nazaraliyev A, Richard E, Sawai CM. In-vivo differentiation of adult hematopoietic stem cells from a single-cell point of view. Curr Opin Hematol. 2020 Jul;27(4):241-247. doi: 10.1097/MOH.0000000000000587. PMID: 32398457.

79: Mourey L, Falandry C, de Decker L, Boulahssass R, Carola E, Bengrine Lefevre L, Cudennec T, Brain E, Paillaud E, Soubeyran P. Taking care of older patients with cancer in the context of COVID-19 pandemic. Lancet Oncol. 2020 May;21(5):e236. doi: 10.1016/S1470-2045(20)30229-1. Epub 2020 Apr 14. PMID: 32302533; PMCID: PMC7156244.

80: Peyraud F, Italiano A. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers (Basel). 2020 Jun 9;12(6):E1502. doi: 10.3390/cancers12061502. PMID: 32526888.

81: Lucchesi C, Drogat B, Santamaria D, Cousin S, Italiano A. Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer. Lung Cancer. 2018 Dec;126:227-229. doi: 10.1016/j.lungcan.2018.10.013. Epub 2018 Oct 12. PMID: 30342857.

82: Italiano A. Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas-Reply. JAMA Oncol. 2018 Aug 1;4(8):1134-1135. doi: 10.1001/jamaoncol.2018.0895. PMID: 29902304.

83: Laroche-Clary A, Chaire V, Verbeke S, Algéo MP, Malykh A, Le Loarer F, Italiano A. ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status. Sci Rep. 2020 May 4;10(1):7488. doi: 10.1038/s41598-020-63294-z. PMID: 32366852; PMCID: PMC7198496.

84: Fourneaux B, Bourdon A, Dadone B, Lucchesi C, Daigle SR, Richard E, Laroche-Clary A, Le Loarer F, Italiano A. Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition. J Hematol Oncol. 2019 Nov 22;12(1):116. doi: 10.1186/s13045-019-0825-3. PMID: 31753040; PMCID: PMC6873665.

85: Italiano A, Bellera C, D’Angelo S. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. J Hematol Oncol. 2020 May 19;13(1):55. doi: 10.1186/s13045-020-00891-5. PMID: 32430039; PMCID: PMC7236113.

86: Mahon FX. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia? Clin Adv Hematol Oncol. 2019 Feb;17(2):101-103. PMID: 30845112.

87: Le Loarer F, Renard C, Ranchere D. Histoséminaire microbiopsie des tissus mous, cas n<sup>o</sup> 2 [Soft tissue tumor with adipocytic differentiation]. Ann Pathol. 2020 Apr 29:S0242-6498(20)30048-1. French. doi: 10.1016/j.annpat.2020.02.012. Epub ahead of print. PMID: 32359934. 88: Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, Kind M, Longy M, Blay JY, Italiano A. Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. Ann Oncol. 2020 Mar 17:S0923-7534(20)36362-6. doi: 10.1016/j.annonc.2020.03.283. Epub ahead of print. PMID: 32194151.

89: Morvan VL, Richard É, Cadars M, Fessart D, Broca-Brisson L, Auzanneau C, Pasquies A, Modesto A, Lusque A, Mathoulin-Pélissier S, Lansiaux A, Robert J. Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma. Br J Cancer. 2020 Jun 22. doi: 10.1038/s41416-020-0932-5. Epub ahead of print. PMID: 32565541.

90: Italiano A. A new standard of care for patients with high-risk rhabdomyosarcoma? Lancet Oncol. 2020 Jan;21(1):e2. doi: 10.1016/S1470-2045(19)30784-3. PMID: 31908302.

91: Garcia Spezza E, Brethon B, Petit A, Mazingue F, Gandemer V, Boissel N, Carausu L, Reguerre Y, Leverger G, Ducassou S. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. Br J Haematol. 2020 Jan;188(1):170-173. doi: 10.1111/bjh.16364. Epub 2019 Dec 6. PMID: 31808943.

92: Etienne G, Dulucq S, Faberes C, Bijou F, Schmitt A, Klein E, Fort MP, Durrieu F, Toulza E, Mahon FX. A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study. Br J Haematol. 2020 May;189(3):e97-e100. doi: 10.1111/bjh.16511. Epub 2020 Feb 10. PMID: 32043283.